Tuesday, 9 March 2010

MSRC comment on Stanford University halting CCSVI treatments after two serious adverse incidents:

From the MSRC Website:

"Helen Yates, Chief Executive of the Multiple Sclerosis Resource Centre (MSRC) said: “Whilst the case of the man who had to have open heart surgery to deal with a slipped stent is accurate, the case of the woman who had a haemorrhage is less so. The lady in question had a pre-existing condition that meant she was much more susceptible to haemorrhage, in fact it has been ascertained since her death that it was nothing to do with the procedure at all and was, in fact, an adverse drug reaction to one of the blood thinning drugs exacerbating a genetic familial problem. The first case is, of course, a reminder that no procedure is without risk and with stenting, there is always a slight risk of the stent coming loose."